Amended: The article, posted on September 17, 2025, about Omeros Corp. (OMER) incorrectly mentioned the PDUFA date as September 25, 2025.
Omeros Corp. (OMER) is approaching a pivotal regulatory milestone as the FDA prepares to issue its decision on the Biologics License Application (BLA) for narsoplimab, the company's lead investigational therapy. The FDA has assigned a PDUFA target action date of December 26, 2025, for its review of narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy/TA-TMA.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com